GoAI
Get started
Alector, Inc. logo

Alector, Inc.

ALEC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.36

+$0.10 · +4.42%

Aug 21, 4:00 PM ET

ALEC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

33

Expensive

Momentum

24

Weakening

Sentiment

56

Mixed

Risk resilience

35

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Arnon Rosenthal
Listed since
Feb 7, 2019
Employees
103

Market position

Day range

Current $2.36

52-week range

Current $2.36

Open
$2.205
Previous close
$2.26
Volume
728.09K
0.83× average
Average volume
874.08K
Average daily volume
Market cap
262.02M USD
Beta
0.58
Market reference 1
50-day average
$1.7511
+34.77% above average
200-day average
$1.8664
+26.45% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
131.11M USD
P/E (TTM)
-2.15×
P/B (TTM)
-26.33×
P/S (TTM)
18.9×
EV / EBITDA
-0.99×
Earnings yield
-88.95%
Free cash flow yield
-114.56%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-360.92%
Operating margin
-914.56%
Net margin
-850.13%
Return on equity
-466.34%
Return on assets
-48.74%
Return on invested capital
-62.54%

Financial health

Debt / equity
-3.29×
Current ratio
3.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends179%-138%-455%-772%Gross margin, FY2021: 8.54%Gross margin, FY2022: 100.00%Gross margin, FY2023: 90.88%Gross margin, FY2024: -84.91%Gross margin, FY2025: 54.09%Operating margin, FY2021: -18.04%Operating margin, FY2022: -103.16%Operating margin, FY2023: -156.33%Operating margin, FY2024: -144.19%Operating margin, FY2025: -692.83%Net margin, FY2021: -17.54%Net margin, FY2022: -99.77%Net margin, FY2023: -134.34%Net margin, FY2024: -118.39%Net margin, FY2025: -679.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 8.54%. Gross margin FY2022 100.00%. Gross margin FY2023 90.88%. Gross margin FY2024 -84.91%. Gross margin FY2025 54.09%. Operating margin FY2021 -18.04%. Operating margin FY2022 -103.16%. Operating margin FY2023 -156.33%. Operating margin FY2024 -144.19%. Operating margin FY2025 -692.83%. Net margin FY2021 -17.54%. Net margin FY2022 -99.77%. Net margin FY2023 -134.34%. Net margin FY2024 -118.39%. Net margin FY2025 -679.16%.

Income trends

Revenue

21.05M USD-79.07%

Operating income

−145.81M USD-0.56%

Net income

−142.93M USD-20.06%
Income trends across reported periods242.97M USD99.44M USD−44.09M USD−187.62M USDRevenue, FY2021: 207.09M USDRevenue, FY2022: 133.62M USDRevenue, FY2023: 97.06M USDRevenue, FY2024: 100.56M USDRevenue, FY2025: 21.05M USDOperating income, FY2021: −37.36M USDOperating income, FY2022: −137.83M USDOperating income, FY2023: −151.74M USDOperating income, FY2024: −145M USDOperating income, FY2025: −145.81M USDNet income, FY2021: −36.33M USDNet income, FY2022: −133.31M USDNet income, FY2023: −130.39M USDNet income, FY2024: −119.05M USDNet income, FY2025: −142.93M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 207.09M USD. Revenue FY2022 133.62M USD. Revenue FY2023 97.06M USD. Revenue FY2024 100.56M USD. Revenue FY2025 21.05M USD. Operating income FY2021 −37.36M USD. Operating income FY2022 −137.83M USD. Operating income FY2023 −151.74M USD. Operating income FY2024 −145M USD. Operating income FY2025 −145.81M USD. Net income FY2021 −36.33M USD. Net income FY2022 −133.31M USD. Net income FY2023 −130.39M USD. Net income FY2024 −119.05M USD. Net income FY2025 −142.93M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue21.05M USD100.56M USD97.06M USD133.62M USD207.09M USD
Cost of goods sold9.66M USD185.94M USD8.85M USD—189.41M USD
Gross profit11.38M USD−85.38M USD88.21M USD133.62M USD17.68M USD
Research and development123.07M USD209.24M USD192.12M USD210.42M USD189.41M USD
Selling, general, and administrative53.99M USD57.41M USD56.69M USD61.03M USD55.04M USD
Operating expenses157.19M USD59.62M USD239.95M USD271.45M USD55.04M USD
Depreciation and amortization9.66M USD8.84M USD8.85M USD8.47M USD8.32M USD
Operating income−145.81M USD−145M USD−151.74M USD−137.83M USD−37.36M USD
Net income−142.93M USD−119.05M USD−130.39M USD−133.31M USD−36.33M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+28.52%
11 comparable reports
Latest EPS result
-0.21
Estimate -0.23 · Beat by 8.12%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.02-0.23-0.44-0.66Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.02, estimate -0.61, surprise +96.72%, Beat. Q2 2025, reported May 8, 2025: actual -0.41, estimate -0.44, surprise +6.82%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.3, estimate -0.45, surprise +33.33%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.34, estimate -0.42, surprise +19.05%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.34, estimate -0.39, surprise +12.82%, Beat. Q2 2026, reported May 7, 2026: actual -0.21, estimate -0.35, surprise +40.00%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.21, estimate -0.229, surprise +8.12%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.24, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates58.5M39.29M20.09M889.1KQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 54.24M USD, estimate 20.4M USD, surprise +165.82%, Beat. Q2 2025, reported May 8, 2025: actual 3.67M USD, estimate 4.25M USD, surprise -13.55%, Miss. Q3 2025, reported Aug 7, 2025: actual 7.87M USD, estimate 2.8M USD, surprise +180.73%, Beat. Q4 2025, reported Nov 6, 2025: actual 3.26M USD, estimate 1.78M USD, surprise +82.77%, Beat. Q1 2026, reported Feb 25, 2026: actual 6.24M USD, estimate 1.96M USD, surprise +218.63%, Beat. Q2 2026, reported May 7, 2026: actual 1.05M USD, estimate 9.67M USD, surprise -89.19%, Miss. Q3 2026, reported Aug 6, 2026: actual 3.32M USD, estimate 1.71M USD, surprise +93.78%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 2.93M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

14 ratings
Strong buy00%
Buy964%
Hold321%
Sell214%
Strong sell00%

Recent analyst actions

8 institutions
William BlairdowngradeOutperformMarket Perform
TD CowendowngradeBuyHold
Morgan StanleydowngradeEqual WeightUnderweight

ALEC news

zacks.com

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.

Read source
globenewswire.com

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's…

Read source
reuters.com

Alector and GSK partnership to end after dementia, Alzheimer's drug failures

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering ​two experimental antibody drugs after both ‌the drug candidates suffered clinical setbacks.

Read source

ALEC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALEC

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.67M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.29M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.86M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.62M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
995.18K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
833.99K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Lazard Emerging Markets Opportunities ETF logoLazard Emerging Markets Opportunities ETFEMKT
Market value
782.36K
Weight
0.43%
AUM
175.2M USD
Expense ratio
0.74%
Price / 1D
$31.505+0.68%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
755.98K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ALEC

research.disclaimer